|
M&A
Shire CEO on NPS Deal: Almost Ideal Timing
Shire’s play to acquire New Jersey-based NPS Pharma comes at nearly ideal timing for the Dublin, Ireland-headquartered firm, explained CEO Dr. Flemming Ornskov in San Francisco, during last week’s 33rd Annual J.P. Morgan Healthcare Conference ...Read more
Global
Europe’s New Competition Commissioner: What Does it Mean for Pharma?
What attitude will the new European commissioner for competition, Margrethe Vestager, adopt toward the pharma industry? The personalities of commissioners should have little influence over the way they conduct business, but, writes Reflector, the very nature of competition law can lend itself to subjective judgements ...Read more
Marketing
The Hidden Forces of Behavioral Economics
Patients and clinicians decide to use or not to use products and brands for reasons that are not always rational. In fact, an overwhelming body of evidence confirms patients and physicians alike often behave "irrationally”
...Read more
Regulatory
IOM Maps Out Clinical Data Sharing Program
Investigators and sponsors of clinical trials will have to make more detailed data available following study completion, according to a new report from an Institute of Medicine expert panel, but they will have several months to disclose individual case reports and complete data supporting registration applications. Jill Wechsler reports
...Read more
Special Feature
What’s Ahead? Pharm Exec’s 2015 Industry Forecast
Following a year where a phenomenal cure was met by pricing outrage, the march of new products and promising immunotherapy cancer combos will continue in 2015. As pharma and tech jell, how will the industry live up to its value supposition while pricing and profiting in the developed and developing worlds? ...Read more
|
